June 2024 Vol 17, No 3

This new feature in The Oncology Pharmacist is a compendium of pioneering work by established and up-and-coming hematology oncology pharmacists and other healthcare providers working in a variety of oncology settings who published abstracts in the March issue of the Journal of Hematology Oncology Pharmacy. Read More ›

The current literature describes various methods by which pharmacists can achieve pharmacovigilance in oncology clinical practice. Finn and colleagues completed a retrospective chart review that showed a 6-fold increase in pharmacovigilance observations via pharmacist interventions with the implementation of EPIC Beacon in the electronic health record (EHR). Read More ›

Second-generation antiandrogens have been studied in 6 large, randomized, double-blind, placebo-controlled, phase 3 clinical trials, PROSPER (enzalutamide), SPARTAN (apalutamide), and ARAMIS (darolutamide) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and TITAN (apalutamide), ARCHES (enzalutamide), and ARASENS (darolutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) populations. This article will review the primary and secondary end points and adverse events (AEs) in these trials. Read More ›

Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›